LOCALLY ADVANCED SOLID TUMORS
Clinical trials for LOCALLY ADVANCED SOLID TUMORS explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED SOLID TUMORS trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets rare gene changes in advanced cancers
Disease control Recruiting nowThis study tests a new drug called repotrectinib in people with advanced solid tumors that have specific gene changes (ALK, ROS1, or NTRK). The goal is to see if the drug can shrink tumors and control the cancer. About 500 adults will take part, and the study has two phases: firs…
Matched conditions: LOCALLY ADVANCED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 06:42 UTC
-
New hope for young cancer patients: targeted drug repotrectinib enters trials
Disease control Recruiting nowThis study tests a drug called repotrectinib in children and young adults (up to age 25) with advanced solid tumors or lymphomas that have specific genetic changes (ALK, ROS1, or NTRK1-3). The first part finds the safest dose, and the second part checks how well the drug shrinks …
Matched conditions: LOCALLY ADVANCED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated May 07, 2026 18:41 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called RO7566802, given alone or with another drug (atezolizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to check the safety and find the best dose. About 250 adults with incurab…
Matched conditions: LOCALLY ADVANCED SOLID TUMORS
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated May 05, 2026 11:54 UTC